<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1025-028X</journal-id>
<journal-title><![CDATA[Vaccimonitor]]></journal-title>
<abbrev-journal-title><![CDATA[Vaccimonitor]]></abbrev-journal-title>
<issn>1025-028X</issn>
<publisher>
<publisher-name><![CDATA[Finlay Ediciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1025-028X2022000200043</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Estudio de intervención con SOBERANA® en los trabajadores del Centro Nacional de Biopreparados]]></article-title>
<article-title xml:lang="en"><![CDATA[Intervention study with SOBERANA® in the workers of the Centro Nacional de Biopreparados]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Reyes-Zamora]]></surname>
<given-names><![CDATA[Mary Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Chávez]]></surname>
<given-names><![CDATA[Suset]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cruz-Quevedo]]></surname>
<given-names><![CDATA[Mileydis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz-Barroso]]></surname>
<given-names><![CDATA[Yamilet]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez-Texidó]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Garcés-Hechavarría]]></surname>
<given-names><![CDATA[Aniurka]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Noda]]></surname>
<given-names><![CDATA[Laura Marta]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Rivera]]></surname>
<given-names><![CDATA[Dagmar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Nacional de Biopreparados  ]]></institution>
<addr-line><![CDATA[Bejucal, Mayabeque ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Finlay de Vacunas  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2022</year>
</pub-date>
<volume>31</volume>
<numero>2</numero>
<fpage>43</fpage>
<lpage>53</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1025-028X2022000200043&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1025-028X2022000200043&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1025-028X2022000200043&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Se presentan los resultados del estudio de intervención realizado en el Centro Nacional de Biopreparados, empresa de BioCubaFarma. La investigación fue promovida por el Instituto Finlay de Vacunas, con el objetivo de evaluar los efectos directos e indirectos de la vacunación anti SARS-CoV-2 con un esquema heterólogo 2P+1: dos dosis de SOBERANA®02 más una dosis de SOBERANA®Plus con 28 días entre ellas, en cohortes poblacionales de riesgo de infección, enfermedad y dispersión de la epidemia. Fueron evaluados 1.007 sujetos, incluyéndose inicialmente 924. De ellos, el 97,62% recibió el esquema completo de vacunación. Posteriormente se incluyeron 21 convalecientes de COVID-19 con al menos dos meses del alta clínica, que recibieron una única dosis de SOBERANA®Plus. La seguridad de las vacunas se evalúo mediante la identificación y clasificación de los eventos adversos por farmacovigilancia activa y pasiva. Se registraron un total de 482 eventos adversos, en su mayoría por farmacovigilancia pasiva, de intensidad leve y de causalidad A1 (relacionados). No ocurrieron eventos adversos graves relacionados. Se realizó cuantificación de IgG anti SARS-CoV-2 a 100 individuos y el 68% tuvo una respuesta mayor o igual de 50 UA/mL, siendo estos sujetos nueve años menores que los de respuesta menor. Hasta los tres meses de concluida la intervención, 64 vacunados fueron diagnosticados con COVID-19 y ninguno de ellos estuvo grave o falleció. Se evidenció un perfil de seguridad muy favorable de SOBERANA® e indicios de efectividad en la prevención de formas graves y mortalidad por COVID-19.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT The results of an intervention study performanced at the Centro Nacional de Biopreparados, a company of BioCubaFarma, are presented. The research was promoted by the Finlay Vaccine Institute, with the aim of evaluating the direct and indirect effects of vaccination against SARS-CoV-2, with a heterologous 2P + 1 scheme: two doses of SOBERANA®02 plus one dose of SOBERANA®Plus with 28 days between them; in population cohorts at risk of infection, disease and spread of the epidemic. A quantity of 1,007 subjects were evaluated and 924 were initially included. Of these, 97.62% received the complete vaccination schedule. Subsequently, 21 convalescents of COVID-19 with at least two months of clinical discharge were included, who received a single dose of SOBERANA®Plus. The safety of the vaccine was evaluated by identifying and classifying adverse events by active and passive pharmacovigilance. A total of 482 adverse events were recorded, mostly due to passive pharmacovigilance, mild intensity and A1 causality (related). No related serious adverse events occurred. IgG anti SARS-CoV-2 was quantified in 100 individuals, and 68% had a response greater than or equal to 50 IU/mL, these subjects being nine years younger than those with a lower response. Up to three months after the intervention, 64 vaccinated people were diagnosed with COVID-19 and none of them were seriously ill or died. A very favorable safety profile of SOBERANA® and indications of effectiveness in preventing severe forms and mortality from COVID-19 were evidenced.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[COVID-19]]></kwd>
<kwd lng="es"><![CDATA[vacunas]]></kwd>
<kwd lng="es"><![CDATA[seguridad]]></kwd>
<kwd lng="en"><![CDATA[COVID-19]]></kwd>
<kwd lng="en"><![CDATA[vaccines]]></kwd>
<kwd lng="en"><![CDATA[safety]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tamayo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eficacia del esquema de vacunación de dos dosis de Soberana 02 y una de Soberana Plus es de 91,2 por ciento]]></article-title>
<source><![CDATA[Granma]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Asociación Médica Mundial</collab>
<article-title xml:lang=""><![CDATA[Declaración de Helsinki de la AMM - Principios éticos para las investigaciones médicas en seres humanos]]></article-title>
<source><![CDATA[64ª Asamblea General]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Fortaleza ]]></publisher-loc>
<publisher-name><![CDATA[Asociación Médica Mundial]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<collab>CECMED</collab>
<article-title xml:lang=""><![CDATA[Reg.No. 45-2007]]></article-title>
<source><![CDATA[Requerimientos para la Notificación y el Reporte de Eventos Adversos Graves e Inesperados en los Ensayos Clínicos]]></source>
<year>2007</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[CECMED]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Causality Assessment of an Adverse Event Following Immunization (AEFI) 2nd Edition]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yaffe]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Las cinco vacunas de Cuba contra el COVID-19: la historia completa sobre Soberana 01/02/Plus, Abdala y Mambisa]]></article-title>
<source><![CDATA[LSE Latin America and Caribbean]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<collab>MINSAP</collab>
<source><![CDATA[Anuario Estadístico de Salud 2020, Dirección Nacional de Registros Médicos y Estadísticas de Salud]]></source>
<year>2021</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[MINSAP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toledo-Romani]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[García-Carmenate]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Valenzuela]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Baldoquin-Rodríguez]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of SOBERANA, a COVID conjugate vaccine in heterologous three-dose combination]]></article-title>
<source><![CDATA[medRxiv]]></source>
<year>2021</year>
<page-range>10.31.21265703</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Puga-Gómez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ricardo-Delagado]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Rojas-Iriarte]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Céspedes-Henriquez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Piedra-Bello]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vega-Mendoza]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children]]></article-title>
<source><![CDATA[medRxiv]]></source>
<year>2022</year>
<page-range>03.03.22271313</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez-Rodríguez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates Safety, reactogenicity and immunogenicity]]></article-title>
<collab>de la Caridad Rodríguez-González M.Ochoa-Azze R.Climent-Ruiz Y.Alberto González-Delgado C.Paredes-Moreno B</collab>
<source><![CDATA[Vaccine]]></source>
<year>2022</year>
<volume>40</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>2068-75</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al Kaabi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Xia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Al Qahtani]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Abdulrazzaq]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2021</year>
<volume>326</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>35-45</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rumbo-Prieto]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reacciones cutáneas asociadas a la vacuna Covid, ¿Qué sabemos]]></article-title>
<source><![CDATA[Enferm Dermatol]]></source>
<year>2021</year>
<volume>15</volume>
<numero>42</numero>
<issue>42</issue>
<page-range>6-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Baly]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Baró]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Menéndez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ruíz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reactogenicidad de la vacuna cubana trivalente contra la leptospirosis humana en un ensayo clínico de fase II]]></article-title>
<source><![CDATA[VacciMonitor]]></source>
<year>2001</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chang-Monteagudo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ochoa-Azze]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Climent-Ruiz]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Macías-Abraham]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Noda]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Valenzuela-Silva]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile An open-label phase 1 clinical trial]]></article-title>
<source><![CDATA[Lancet Reg Health Am]]></source>
<year>2021</year>
<volume>4</volume>
<page-range>100079</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Logunov]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
<name>
<surname><![CDATA[Dolzhikova]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Shcheblyakov]]></surname>
<given-names><![CDATA[DV]]></given-names>
</name>
<name>
<surname><![CDATA[Tukhvatulin]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Zubkova]]></surname>
<given-names><![CDATA[OV]]></given-names>
</name>
<name>
<surname><![CDATA[Dzharullaeva]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine an interim analysis of a randomised controlled phase 3 trial in Russia]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2021</year>
<volume>397</volume>
<numero>10275</numero>
<issue>10275</issue>
<page-range>671-81</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baden]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[El Sahly]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Essink]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kotloff]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Frey]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Novak]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
<volume>384</volume>
<page-range>403-16</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rouphael]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Makhene]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Coler]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An mRNA vaccine against SARS-CoV-2-preliminary report]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>383</volume>
<page-range>1920-31</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[Guan]]></surname>
<given-names><![CDATA[XH]]></given-names>
</name>
<name>
<surname><![CDATA[Hou]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[JX]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine a dose-escalation, open-label, non-randomised, first-in-human trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2020</year>
<volume>395</volume>
<numero>10240</numero>
<issue>10240</issue>
<page-range>1845-54</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<collab>Colegio Oficial de Farmacéuticos de Madrid</collab>
<article-title xml:lang=""><![CDATA[Seguridad de las vacunas frente a la COVID-19]]></article-title>
<source><![CDATA[]]></source>
<year></year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Colegio Oficial de Farmacéuticos de Madrid]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mathioudakis]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Ghrew]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ustianowski]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmad]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Borrow]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Papavasileiou]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines A Vaccine Recipient Survey]]></article-title>
<source><![CDATA[Life]]></source>
<year>2021</year>
<volume>11</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>249</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santucci]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Villar]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Valoración inmunológica de las vacunas COVID-19]]></article-title>
<source><![CDATA[IntraMed]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<collab>Organización Panamericana de la Salud</collab>
<source><![CDATA[Reporte de Situación COVID-19 Cuba No. 78]]></source>
<year>2021</year>
<publisher-loc><![CDATA[Washington DC ]]></publisher-loc>
<publisher-name><![CDATA[OPS]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
